MarketResearchNest.com adds “Global Lung Cancer Liquid Biopsy Market 2017-2021” new reports to its research database. The report spread across 109 pages with tables and figures in it.
The analysts forecast the global lung cancer liquid biopsy market to grow at a CAGR of 17.15% during the period 2017-2021.
A liquid biopsy helps to identify free-floating tumor DNA (also known as circulating DNA) within the blood sample of a patient. Lung cancer liquid biopsy helps to detect the epidermal growth factor receptor (EGFR) mutation and other identified mutations, which are responsible for lung cancer. It is observed that the use of a liquid biopsy to identify carcinogenic cells of lungs will help in the early diagnosis of lung cancer.
Get more details about report at https://www.marketresearchnest.com/global-lung-cancer-liquid-biopsy-market-2017-2021.html .
Technavio recognizes the following companies as the key players in the global Lung Cancer Liquid Biopsy market: Alere, bioMérieux, Church & Dwight, and Quidel.
Other Prominent Vendors in the market are: Clinical Guard, Fairhaven Health, Germaine Laboratories, MAP Sciences, Mankind Pharma, PRIMA Lab, Princeton BioMeditech, Wondfo, and Zita West.
Commenting on the report, an analyst team said: “One trend in the market is increasing demand for home diagnostic kits. The fast-paced lifestyle has increased the working and traveling hours leaving very little time for oneself. This is increasing the demand for products that provide instant results such as home diagnostic kits. Often seen as more convenient and less time-consuming alternative to a trip to the doctor’s office, self-testing or home diagnostic and monitoring devices are increasing in sales.”
Request a Sample Copy at https://www.marketresearchnest.com/requestsample.php?reportid=283148 .
According to the report, one driver in the market is rise in first-time pregnancy age. The first-time pregnancy age is increasing around the world. Earlier the first-time pregnancy age which was 22-30 years, which has now increased to 27-35 years, globally? The delay in first-time pregnancy age is due to many factors including higher education, interest in pursuing a career, economic pressure, and problems in relationships, thus postponing marriage and motherhood to 30 years and above. Increasing interest in higher education and increased use of contraceptives have resulted in women using long-acting forms of birth control, thus declining unplanned pregnancies.
Further, the report states that one challenge in the market is preference for alternative tests. When pregnancy test kits were introduced in the market, the primary driver was the privacy they offered. However, women are increasingly growing comfortable with obstetricians testing for pregnancy, regardless of their marital status. Apart from this, obstetricians and gynecologists also provide accuracy and guidance, inducing the preference for clinical pregnancy tests over self-tests taken at home. Furthermore, women with other related complications such as concerns related to weight, and are planning to start a family prefer visiting a professional instead of taking a home test. Also, in countries such as the US, preference for clinical tests over pregnancy detection kits is further fueled by young women being eligible for health insurance through the Affordable Care Act.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=283148 .
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain
+1-240-284-8070 / +44-20-3290-4151